OPTINOSE INC (OPTN)

US68404V1008 - Common Stock

1.48  0 (0%)

Premarket: 1.46 -0.02 (-1.35%)

News Image
13 days ago - Chartmill

These stocks are moving in today's after hours session

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

News Image
13 days ago - Optinose, Inc.

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps

News Image
21 days ago - InvestorPlace

OPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023

OPTN stock results show that OptiNose met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

News Image
21 days ago - BusinessInsider

OPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips OptiNose (NASDAQ:OPTN) just reported results for the fourth quarter of 2023.Opt...

News Image
21 days ago - Optinose, Inc.

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients...

News Image
a month ago - Optinose, Inc.

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time

News Image
a month ago - Optinose, Inc.

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time

News Image
2 months ago - Optinose, Inc.

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized...

News Image
4 months ago - Optinose, Inc.

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in...

News Image
4 months ago - Optinose, Inc.

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat...

News Image
5 months ago - Optinose, Inc.

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in...

News Image
5 months ago - Optinose, Inc.

Optinose Announces Reporting Date for Third Quarter 2023 Financial Results

Conference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern Time

News Image
6 months ago - Optinose, Inc.

Optinose to Present at the 2023 Cantor Global Healthcare Conference

YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat...

News Image
8 months ago - Optinose, Inc.

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in...

News Image
8 months ago - Optinose, Inc.

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE...

News Image
10 months ago - Optinose, Inc.

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and...